It is sensible that the elevated enrichment of CD8+ T cell, B cell, NK cell, cytolytic activity, HLA, immune cell infiltrate, TILs, and CCR is associated with favorable clinical outcomes in cancer since these immune signatures can promote anticancer immune response. The gene discussed is CD8A; the disease is cancer.